PT  - JOURNAL ARTICLE
AU  - Shuman, Jill
ED  - Trainer, Peter J.
TI  - ATL1103 Effective in Reducing IGF-1 Levels in Patients With Acromegaly
DP  - 2015 Jun 18
TA  - MD Conference Express
PG  - 14--15
VI  - 15
IP  - 4
4099  - http://mdc.sagepub.com/content/15/4/14.2.short
4100  - http://mdc.sagepub.com/content/15/4/14.2.full
AB  - Acromegaly is caused by an overproduction of growth hormone, and subsequently, insulin-like growth factor-I. ALT1103 is second-generation drug that reduces expression of the growth hormone receptor. In a phase 2 trial, patients with acromegaly who received 400 mg of ALT1103 showed a significant reduction in insulin-like growth factor-I at 14 weeks.